NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova Allograft
Benzinga Newsdesk 3 years ago
News
NovaBay Pharmaceuticals, Inc. (NYSE:NBY) and BioStem Technologies, Inc. (OTC:BSEM) announce an agreement under which NovaBay has been granted the right to commercialize BioStem Technologies' Amniotic Tissue
NovaBay Pharmaceuticals, Inc. (NYSE:NBY) and BioStem Technologies, Inc. (OTC:BSEM) announce an agreement under which NovaBay has been granted the right to commercialize BioStem Technologies' Amniotic Tissue Allograft, which is intended for use as a protective covering during the repair of ocular surfaces.